121 results
Page 4 of 7
8-K
EX-99.1
ngcuqh
28 Apr 21
Alkermes plc Reports First Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
r33no1algv
25 Mar 21
Regulation FD Disclosure
12:00am
8-K
EX-99.2
14iu2bvi0g3fsjkp4mnm
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
gztl1bt1
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
bo71eq80 dtznnq
6 Jan 21
Alkermes Announces Updates to Executive Leadership Team
4:24pm
8-K
EX-99.1
pxado3z8r w6iug7
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-10.1
50c86q
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-99.1
v7f nsnhmh65a4
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
EX-99.2
ofvbp5kw563 7lc
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.1
j3w9q8wi lofm3i5
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm
8-K
EX-99.1
awhtqry7
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.2
apg24uz kiyr49wj
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am
8-K
EX-99.1
dq25zt76r8o dw14v6yw
18 Nov 19
Alkermes to Acquire Rodin Therapeutics
7:16am
8-K
EX-99.1
5efu41b7cdf0oh
13 Sep 19
Departure of Directors or Certain Officers
7:22am
8-K
EX-99.1
pfl vqavcd4z65w6
15 Jul 19
Regulation FD Disclosure
7:33am
DEFA14A
2m6qm uf17hb27e8mi
15 May 19
Additional proxy soliciting materials
12:32pm
8-K
EX-99.1
el87snze bc7u418jgiu
25 Apr 19
Alkermes Plc Reports First Quarter 2019 Financial Results
7:05am